Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor–G protein coupling and Gβγ signaling

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Neuroscience

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.NEUROSCIENCE.2005.06.003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.

  2005cited by this paper
• Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats

  2005cited by this paper
• Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats.

  2005cited by this paper
• D2 Dopamine Receptors Modulate Gα-Subunit Coupling of the CB1 Cannabinoid Receptor

  2004influential reference
• Basal Signaling Activity of μ Opioid Receptor in Mouse Brain: Role in Narcotic Dependence

  2004cited by this paper
• Naloxone and its quaternary derivative, naloxone methiodide, have differing affinities for μ, δ, and κ opioid receptors in mouse brain homogenates

  2003cited by this paper
• Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone.

  2003cited by this paper
• Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats.

  2002influential reference
• Molecular neurobiology of addiction.

  2001cited by this paper
• Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia.

  2001cited by this paper
• Stimulated D1 dopamine receptors couple to multiple Gα proteins in different brain regions

  2001influential reference
• ACh‐induced rebound stimulation of L‐type Ca2+ current in guinea‐pig ventricular myocytes, mediated by Gβγ‐dependent activation of adenylyl cyclase

  2001cited by this paper
• Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin.

  2001cited by this paper
• Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability

  2000cited by this paper
• Basic Fibroblast Growth Factor Utilizes Both Types of Component Subunits of Gsfor Dual Signaling in Human Adipocytes: STIMULATION OF ADENYLYL CYCLASE VIA GαsAND INHIBITION OF NADPH OXIDASE BY Gβγs

  2000cited by this paper
• μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence

  2000influential reference
• Overexpression of type 7 adenylyl cyclase in the mouse brain enhances acute and chronic actions of morphine.

  2000cited by this paper
• Altered pain responses in mice lacking α1E subunit of the voltage-dependent Ca2+ channel

  2000cited by this paper
• Gβγ subunit combinations differentially modulate receptor and effector coupling in vivo

  2000cited by this paper
• Opioid tolerance and the emergence of new opioid receptor-coupled signaling

  2000influential reference
• Involvement of G-protein-activated inwardly rectifying K (GIRK) channels in opioid-induced analgesia.

  2000cited by this paper
• OPIOID RECEPTOR SIGNALLING MECHANISMS

  1999cited by this paper
• Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia.

  1999cited by this paper
• Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses.

  1998cited by this paper
• The role of receptor kinases and arrestins in G protein-coupled receptor regulation.

  1998cited by this paper
• 3H-naloxone benzoylhydrazone binding in MOR-1-transfected Chinese hamster ovary cells: evidence for G-protein-dependent antagonist binding.

  1998cited by this paper
• Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions.

  1998cited by this paper
• Altered μ‐Opiate Receptor‐G Protein Signal Transduction Following Chronic Morphine Exposure

  1997influential reference
• Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A

  1997cited by this paper
• Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice.

  1997cited by this paper
• Opioid‐sparing Effects of a Low‐dose Infusion of Naloxone in Patient‐administered Morphine Sulfate

  1997cited by this paper
• The role of self-administration in morphine withdrawal in rats

  1997cited by this paper
• G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins.

  1996cited by this paper
• Receptor‐Mediated Activation of G Proteins Is Increased in Postmortem Brains of Bipolar Affective Disorder Subjects

  1996cited by this paper
• Adenylylcyclase Supersensitization in μ-Opioid Receptor-transfected Chinese Hamster Ovary Cells Following Chronic Opioid Treatment (*)

  1995cited by this paper
• Characterization of Irreversible Binding of -Funaltrexamine to the Cloned Rat Opioid Receptor (*)

  1995cited by this paper
• Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.

  1995influential reference
• Binding of Human High-molecular-weight Salivary Mucins (MG1) to Hemophilus parainfluenzae

  1995cited by this paper
• Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence.

  1994cited by this paper
• Analysis of receptor-stimulated and basal guanine nucleotide binding to membrane G proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

  1993cited by this paper
• μ and δ opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells

  1993influential reference
• After chronic opioid exposure sensory neurons become supersensitive to the excitatory effects of opioid agonists and antagonists as occurs after acute elevation of GM1 ganglioside.

  1992cited by this paper
• Hormonal stimulation of adenylyl cyclase through Gi-protein βγ subunits

  1992cited by this paper
• Type-specific regulation of adenylyl cyclase by G protein beta gamma subunits.

  1991cited by this paper
• Cholera toxin-A subunit blocks opioid excitatory effects on sensory neuron action potentials indicating mediation by Gs-linked opioid receptors.

  1990cited by this paper
• Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons.

  1990cited by this paper
• Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture.

  1989cited by this paper
• Morphine: some puzzles of well-known substance.

  1989cited by this paper
• Clinical experience of long–term treatment with epidural and intrathecal opioids – a nationwide survey

  1988cited by this paper
• A selective kappa-opioid agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats.

  1988cited by this paper
• Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund's adjuvant-induced arthritic rats).

  1987cited by this paper

• Effect of Ultra-low-dose Naloxone on Ileus after Cesarean Section: A Randomized Clinical Trial

  2026cites this paper
• Low dose naloxone mitigates opioid tolerance and dependence and restores mesenchymal stem cell function for cell therapy in addiction

  2025cites this paper
• De novo expression of neuropeptide Y in sensory neurons does not contribute to peripheral neuropathic pain.

  2025cites this paper
• Diffuse Noxious Inhibitory Controls in Chronic Pain States: Insights from Pre-Clinical Studies

  2025cites this paper
• Plumbagin Attenuates Neuropathic Pain via Inhibition of Spinal Astrogliosis and Modulation of Hippocampal CA1 Opioidergic Receptors

  2025cites this paper
• Impact of chronic opioid use on acute health care utilization in children with IBD and arthritis: a retrospective cohort study

  2024cites this paper
• Effective Doses of Low-Dose Naltrexone for Chronic Pain – An Observational Study

  2024cites this paper
• Neuropeptide Y Y2 receptors in acute and chronic pain and itch.

  2024cites this paper
• The efficacy of nalmefene on anesthetic recovery of patients: a study protocol for a multicenter randomized controlled trial

  2023cites this paper
• How do opioids control pain circuits in the brainstem during opioid-induced disorders and in chronic pain? Implications for the treatment of chronic pain.

  2023cites this paper
• Naloxone could limit morphine hypersensitivity: Considering the molecular mechanisms.

  2023cites this paper
• Endogenous opioid systems alterations in pain and opioid use disorder

  2022cites this paper
• The role of the type 7 adenylyl cyclase isoform in alcohol use disorder and depression

  2022cites this paper
• Restoring the Neuroprotective Capacity of Glial Cells Under Opioid Addiction

  2022cites this paper
• Central blockade of orexin type 1 receptors reduces the naloxone induced activation of locus coeruleus neurons in the morphine dependent rats.

  2021cites this paper
• Evaluating oliceridine as a treatment option for moderate to severe acute post-operative pain in adults

  2021cites this paper
• Low-Dose Naltrexone Co-Treatment in the Prevention of Opioid-Induced Hyperalgesia

  2021cites this paper
• Addressing opioid tolerance and opioid‐induced hypersensitivity: Recent developments and future therapeutic strategies

  2021cites this paper
• Investigating the effect of Ultra-low dose naloxone on spinal BDNF and KCC2 cotransporter in morphine tolerant and hyperalgesia rats

  2020influential citation
• Opioid use among patients with inflammatory bowel disease: A systematic review and meta-analysis.

  2020cites this paper
• Shift of µ-opioid Receptor Signaling in the Dorsal Reticular Nucleus Is Implicated in Morphine-induced Hyperalgesia in Male Rats

  2020cites this paper
• Disappearance of the inhibitory effect of neuropeptide Y within the dorsolateral bed nucleus of the stria terminalis in rats with chronic pain.

  2020cites this paper
• Reconsidering the Usefulness of Adding Naloxone to Buprenorphine

  2020cites this paper
• Mu and delta opioid receptors play opposite nociceptive and behavioural roles on nerve‐injured mice

  2020cites this paper
• Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential.

  2019cites this paper
• Nitric oxide modulates μ‐opioid receptor function in vitro

  2019cites this paper
• A Differential Hypofunctionality of Gαi Proteins Occurs in Adolescent Idiopathic Scoliosis and Correlates with the Risk of Disease Progression

  2019cites this paper
• Opioid and Cannabis Co-Use among Adults with Chronic Pain: Relations to Substance Misuse, Mental Health, and Pain Experience.

  2019cites this paper
• μ‐Opioid receptors in primary sensory neurons are essential for opioid analgesic effect on acute and inflammatory pain and opioid‐induced hyperalgesia

  2019cites this paper
• Opioid Toxicity in Inflammatory Bowel Disease Patients Likely Includes Direct Enterocyte Effects That Exacerbate Disease.

  2018cites this paper
• Altered Signaling in the Descending Pain-modulatory System after Short-Term Infusion of the μ-Opioid Agonist Remifentanil

  2018cites this paper
• Enhancement of Meditation Analgesia by Opioid Antagonist in Experienced Meditators

  2018cites this paper
• Why mu‐opioid agonists have less analgesic efficacy in neuropathic pain?

  2018cites this paper
• Role of the guanine nucleotide binding protein, Gαo, in the development of morphine tolerance and dependence

  2017influential citation
• The role of oxycodone/naloxone in pain management

  2017cites this paper
• Intraoperative naloxone reduces remifentanil-induced postoperative hyperalgesia but not pain: a randomized controlled trial

  2017cites this paper
• Naloxone prolongs cutaneous nociceptive block by lidocaine in rats

  2017cites this paper
• The role of morphine on rat neural stem cells viability, neuro-angiogenesis and neuro-steroidgenesis properties.

  2017cites this paper
• Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis

  2016cites this paper
• Naloxone blocks the aversive effects of electrical stimulation of the parabrachial complex in a place discrimination task.

  2016cites this paper
• Morphine Inhibited the Rat Neural Stem Cell Proliferation Rate by Increasing Neuro Steroid Genesis

  2016cites this paper
• A randomized controlled study of the effects of adding ultra-low dose naloxone to lidocaine for intravenous regional anesthesia

  2016cites this paper
• Clinical Assessment Tools: Quantitative Sensory Testing

  2016cites this paper
• Contribution of adrenomedullin to the switch of G protein‐coupled μ‐opioid receptors from Gi to Gs in the spinal dorsal horn following chronic morphine exposure in rats

  2016influential citation
• Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction–Recommendations of the Nordic Working Group

  2016cites this paper
• Attenuation of morphine tolerance, reward, and spinal gliosis in neuropathic pain by ultra-low dose alpha2-adrenergic antagonists

  2016cites this paper
• Molecular Changes in Opioid Addiction: The Role of Adenylyl Cyclase and cAMP/PKA System.

  2016cites this paper
• Therapeutic innovation: Inflammatory-reactive astrocytes as targets of inflammation

  2016cites this paper
• Glial dysfunction and persistent neuropathic postsurgical pain

  2016cites this paper
• The Role of the δ Opioid Receptor Gene, OPRD1 , in Addiction

  2016cites this paper
• Chronic loss of noradrenergic tone produces β‐arrestin2‐mediated cocaine hypersensitivity and alters cellular D2 responses in the nucleus accumbens

  2016cites this paper
• A randomized clinical trial of the effects of ultra‐low‐dose naloxone infusion on postoperative opioid requirements and recovery

  2015cites this paper
• Biased signalling: the instinctive skill of the cell in the selection of appropriate signalling pathways.

  2015cites this paper
• An Evaluation of Factors Related to Postoperative Pain Control in Burn Patients

  2015cites this paper
• Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to Alter Persistent Pain

  2015cites this paper
• μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids.

  2015cites this paper
• Usos terapéuticos potenciales de los antagonistas opioides: Fisiopatología y evidencia preclínica

  2015cites this paper
• Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations

  2015cites this paper
• Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids

  2015cites this paper
• Endocannabinoids and epilepsy

  2015cites this paper
• Naloxone added to bupivacaine or bupivacaine–fentanyl prolongs motor and sensory block during supraclavicular brachial plexus blockade: a randomized clinical trial

  2015cites this paper
• (+)-Naloxone inhibits morphine-induced chemotaxis via prevention of heat shock protein 90 cleavage in microglia.

  2015cites this paper
• Combining an oral opioid-receptor agonist and the antagonist naloxone: A smart drug design that removes some but not all adverse effects of the opioid analgesic

  2014cites this paper
• Combined Administration of Oxycodone/Naloxone in Chronic Osteo-Articular Diseases Pain Therapy

  2014cites this paper
• ENHANCING PERIPHERAL OPIOID ANALGESIA: DEVELOPMENT OF VIRAL VECTOR AND SMALL PEPTIDE THERAPIES

  2014cites this paper
• Inhibitory effect of spinal mGlu(5) receptor antisense oligonucleotide on the up-regulated expression of spinal G protein associated with chronic morphine treatment.

  2014cites this paper
• Acute morphine alters GABAergic transmission in the central amygdala during naloxone-precipitated morphine withdrawal: role of cyclic AMP

  2014cites this paper
• Prenatal Cocaine Exposure Uncouples mGluR1 from Homer1 and Gq Proteins

  2014cites this paper
• A novel controlled release drug delivery system for naltrexone administration combined with intermittent morphine to induce antinociception

  2014cites this paper
• Actin Filament Reorganization in Astrocyte Networks is a Key Functional Step in Neuroinflammation Resulting in Persistent Pain: Novel Findings on Network Restoration

  2014cites this paper
• A new concept affecting restoration of inflammation-reactive astrocytes.

  2013cites this paper
• Activation of Mas oncogene-related gene (Mrg) C receptors enhances morphine-induced analgesia through modulation of coupling of μ-opioid receptor to Gi-protein in rat spinal dorsal horn.

  2013cites this paper
• OPIOIDS AND GLIA: INVESTIGATING THE MECHANISMS THROUGH WHICH ULTRA-LOW DOSE OPIOID ANTAGONISTS MODULATE OPIOID TOLERANCE AND HYPERALGESIA.

  2013cites this paper
• Intrathecal Ultra-Low Dose Naloxone Enhances the Antihyperalgesic Effects of Morphine and Attenuates Tumor Necrosis Factor-&agr; and Tumor Necrosis Factor-&agr; Receptor 1 Expression in the Dorsal Horn of Rats with Partial Sciatic Nerve Transection

  2013cites this paper
• Nitric Oxide in the Hippocampal Cortical Area 1 (CA1) Augments the Naloxone-induced Place Aversion

  2013cites this paper
• Endorphinergic Attenuation of Distress by Concomitantly Enhancing Endogenous Opioid Release and Switching Opioid Receptor Signaling from an Excessively Excitatory to a Normal Inhibitory Mode

  2013cites this paper
• Opioid antagonists for pain

  2013cites this paper
• Ultra-low dose (+)-naloxone restores the thermal threshold of morphine tolerant rats.

  2013cites this paper
• The stereoisomer (+)-naloxone potentiates G-protein coupling and feeding associated with stimulation of mu opioid receptors in the parabrachial nucleus

  2013cites this paper
• Challenges for Pain Management in the Twenty-First Century

  2013cites this paper
• Oxycodone combined with opioid receptor antagonists: efficacy and safety

  2013cites this paper
• Studies on the Role of G Protein Alpha Subunits in Opioid Signaling and Behavior.

  2013cites this paper
• Pacjent z opornym bólem, leczony dużymi dawkami opioidów. Czy możemy uniknąć zwiększania dawki opioidów?

  2013cites this paper
• Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?

  2013cites this paper
• A patient with intractable pain on high dose opioid therapy. Could we manage not to escalate the opioid dose

  2012cites this paper
• Evidence from basic research for opioid combinations

  2012cites this paper
• Ser/ Thr residues at α3/β5 loop of Gαs are important in morphine‐induced adenylyl cyclase sensitization but not mitogen‐activated protein kinase phosphorylation

  2012cites this paper
• Mechanisms of mu opioid receptor mediated protection from multiple models of acute injury

  2012cites this paper
• Naloxone in ultralow concentration restores endomorphin-1-evoked Ca²⁺ signaling in lipopolysaccharide pretreated astrocytes.

  2012cites this paper
• The Optimal Dose of Prophylactic Intravenous Naloxone in Ameliorating Opioid-Induced Side Effects in Children Receiving Intravenous Patient-Controlled Analgesia Morphine for Moderate to Severe Pain: A Dose Finding Study

  2011cites this paper
• CAN REPEATED EXPOSURE TO MORPHINE CHANGE THE SPINAL ANALGESIC EFFECTS OF LIDOCAINE IN RATS? (SHORT COMMUNICATION)

  2011cites this paper
• Quantitative Detection of µ Opioid Receptor: Western Blot Analyses Using µ Opioid Receptor Knockout Mice

  2011cites this paper
• Opioids in chronic non-cancer pain

  2011cites this paper
• Can repeated exposure to morphine change the spinal analgesic effects of lidocaine in rats?*

  2011cites this paper
• Immunohistochemical localization of mu opioid receptor in the marginal division with comparison to patches in the neostriatum of the rat brain

  2011cites this paper
• Reversal effect of intra-central amygdala microinjection of L-arginine on place aversion induced by naloxone in morphine conditioned rats.

  2011cites this paper
• Contribution of G inhibitory protein alpha subunits in paradoxical hyperalgesia elicited by exceedingly low doses of morphine in mice.

  2011cites this paper
• Acute Pain Management in Opioid-Tolerant Patients: A Growing Challenge

  2011cites this paper
• -Signaling Pathways of Adenylyl Cyclases 2+ Regulation by Ca

  2011cites this paper
• Regulation by Ca2+-signaling pathways of adenylyl cyclases.

  2011cites this paper